Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported positive results of Phase III study which evaluated the efficacy of Cialis (tadalafil) tablets in men with erectile dysfunction (ED) and benign prostatic hyperplasia (BPH).
Subscribe to our email newsletter
The Phase III randomized, double-blind, placebo-controlled, parallel-design clinical study, assessed the safety and efficacy of Cialis 2.5 or 5 mg for once daily use in 606 sexually active men.
Lilly submitted the study in the supplemental new drug application to the US Food and Drug Administration (FDA) last year seeking approval for Cialis as a treatment for ED and BPH.
The study is available online in The Journal of Sexual Medicine.